Results 61 to 70 of about 15,755 (201)

Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Scientific Reports, 2021
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials
Szabolcs Kiss, Noémi Gede, Péter Hegyi, Bettina Nagy, Rita Deák, Fanni Dembrovszky, Stefania Bunduc, Bálint Erőss, Tamás Leiner, Zsolt Szakács, Hussain Alizadeh   +10 more
doaj   +1 more source

Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma

Blood Science, 2022
Plasmablastic lymphoma (PBL) is an aggressive lymphoma with limited treatment strategies. Tuberculosis (TB) infection poses a high risk for patients with hematologic malignancies, especially those treated with immune agents but were never reported post ...
Wenyue Cao, Yuling Wan, Xingcheng Yang, Wei Huang, Jia Wei   +4 more
doaj   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Monoclonal antibodies applied in treatment for hematological malignancies [PDF]

, 2018
Monoklonska protutijela su protutijela monovalentnog afiniteta (vežu isti epitop) nastala iz klonova jedinstvene roditeljske B-stanice. Otkriće tehnologije hibirdoma stanica omogućilo je dobivanje mišjih monoklonskih protutijela na željeni antigen, a ...
Lugar, Marija
core   +2 more sources

New agents in the Treatment of Myeloma Bone Disease [PDF]

, 2017
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation.
Chantry, A.D., Jolley, I., Lawson, M.A., Ring, E.S., Snowden, J.A.   +4 more
core   +2 more sources

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Haematologica, 2020
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja Weisel, Michele Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios A. Dimopoulos   +18 more
doaj   +1 more source

Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma [PDF]

, 2017
Immunoglobulin G (IgG) metabolism has received much attention in the literature for two reasons: (i) IgG homeostasis is regulated by the neonatal Fc receptor (FcRn), by a pH-dependent and saturable recycling process, which presents an interesting ...
Arnulf, Bertrand, Avet-Loiseau, Hervé, Chappell, Michael J., Decaux, Olivier, Dejoie, Thomas, Evans, Neil D., Fouquet, Guillemette, Guidez, Stéphanie, Harding, Stephen, Harel, Stéphanie, Hebraud, Benjamin, Javaugue, Vincent, Kendrick, Felicity, Leleu, Xavier, Moreau, Philippe, Richez, Valentine, Schraen, Susanna, Touzeau, Cyrille   +17 more
core   +2 more sources

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Haematologica, 2018
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or ...
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos   +36 more
doaj   +1 more source

Mieloma múltiplo: evolução e novas terapêuticas [PDF]

, 2016
Monografia realizada no âmbito da unidade de Estágio Curricular do Mestrado Integrado em Ciências Farmacêuticas, apresentada à Faculdade de Farmácia da Universidade de CoimbraO Mieloma Múltiplo é uma doença hematológica maligna caracterizada pela ...
Sancho, Inês Filipa Góis
core